Clinical trials: Envafolimab
Metastatic Colorectal Cancer
Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.
The goal of this single-arm study is to evaluate the efficacy and safety of Envafolimab combined with Trifluridine/Tipiracil and Bevacizumab in the treatment of metastatic colorectal cancer patients who are refractory or…
- Trial name
- NCT06060704
- Testing
- Envafolimab, Trifluridine/Tipiracil, Bevacizumab
- Where
- China
- Volunteers
- 33 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Lung Cancer, Small Cell
Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin
This prospective, randomized, controlled phase II study aims to evaluate the efficacy of combination therapy with Envafolimab and chemotherapy in first-line extensive stage SCLC, as well as the impact of Trilaciclib on the…
- Trial name
- NCT06698965
- Testing
- Chemotherapy （Etoposide and Carboplatin）, Immunotherapy （Envafolimab）, Trilaciclib
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Shanghai Chest Hospital
Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma
This is a multicenter open-label, randomized, non-comparative, parallel cohort pivotal study of treatment with envafolimab (cohort A and C) or envafolimab combined with ipilimumab (cohort B and D) in patients with locally…
- Trial name
- ENVASARC (NCT04480502)
- Testing
- Envafolimab, Ipilimumab
- Where
- 30 sites in United States, United Kingdom
- Volunteers
- 207 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Non-Small-Cell Lung
First-line Replacement Maintenance of Envafolimab in Advanced NSCLC
This study is a single-center, prospective, single-arm phase II clinical study. For newly-treated patients with advanced NSCLC with negative driver gene and positive PD-L1 expression, those patients who did not progress after 4-6…
- Trial name
- NSCLC (NCT05465733)
- Testing
- Envafolimab;Pemetrexed
- Where
- China
- Volunteers
- 25 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Progression Free Survival(PFS)
Safety and Efficacy Analysis of Oral Etoposide Combined With Anlotinib and Envafolimab in First-line Treatment of Elderly Patients With Small Cell Lung Cancer/ Open-label, Single-arm, Exploratory Phase II Clinical Study
This study aims to explore the safety and efficacy of etoposide capsules combined with Anlotinib and Envafolimab in elderly patients with extensive small cell lung cancer.This is a single-center, single-arm exploratory clinical…
- Trial name
- NCT05685550
- Testing
- Toposide capsules combined with Anlotinib and Envafolimab group
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced Renal Cell Carcinoma (aRCC)
Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
Introduction: This document explains a clinical research study conducted at Peking Union Medical College Hospital. The study aims to evaluate a new combination treatment - Envafolimab (an immunotherapy) and Axitinib (a targeted…
- Trial name
- NCT07159191
- Testing
- Envafolimab Injection, Axitinib Tablets
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Advanced Biliary Tract Cancers
A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy.
This is a prospective, single-arm, Phase II study evaluating sacituzumab tirumotecan combined with envafolimab in patients with TROP2-positive advanced biliary tract cancers who have progressed on first-line immunochemotherapy.
- Trial name
- NCT07729033
- Testing
- Sacituzumab tirumotecan combined with envafolimab
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
NSCLC
A Study of Local Envafolimab Injection Combined With Chemotherapy in Non-small Cell Lung Cancer
The aim of this single-arm, exploratory clinical study is to evaluate the safety and efficacy of local injection of envafolimab combined with chemotherapy in the first-line treatment of non-small cell lung cancer (NSCLC)…
- Trial name
- NCT06108726
- Testing
- Envafolimab Injection
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Northern Jiangsu People's Hospital
Lung Neoplasms
The Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS-SCLC
To evaluate the efficacy and safety of envafolimab combined with concurrent chemoradiotherapy in limited stage small cell lung cancer.
- Trial name
- NCT05904015
- Testing
- Envafolimab combined with concurrent chemoradiotherapy (Hypofractionated radiotherapy), Envafolimab combined with concurrent chemoradiotherapy (Conventional Radiotherapy)
- Volunteers
- 80 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Nasopharyngeal Carcinoma
Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.
This is a single-center, prospective, single-arm, phase II clinical study, to evaluate the therapeutic efficacy and safety of envafolimab combined with chemoradiotherapy and recombinant human endostatin in patients with locally…
- Trial name
- NCT06059261
- Testing
- Envafolimab and recombinant human endostatin combined with chemoradiotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chongqing University Cancer Hospital
Non-small Cell Lung Cancer
Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC
This is a randomized, controlled, double-blind, multicenter Phase 3 clinical study to assess the efficacy and safety of envafolimab plus platinum-based doublet chemotherapy versus placebo plus platinum-based doublet chemotherapy…
- Trial name
- NCT06123754
- Testing
- Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection
- Where
- China
- Volunteers
- 390 people
- Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
Advanced or Metastatic Solid Tumors
A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients
This is a phase I, open-label, multi-center, dose escalation and expansion study in advanced or metastatic solid tumor patients.
- Trial name
- NCT07260305
- Testing
- KGX101 injection, Envafolimab
- Where
- 3 sites in China
- Volunteers
- 57 people
- Sponsor
- Kangabio AUSTRALIA LTD PTY
Clear Cell Renal Cell Cancer (ccRCC), Liver Metastasis
A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread
This is an open-label, single-arm, prospective, multicenter clinical study designed to evaluate the efficacy and safety of envafolimab in combination with lenvatinib for the treatment of patients with clear cell renal cell…
- Trial name
- NCT07256223
- Testing
- Envafolimab+Lenvatinib
- Volunteers
- 30 people
- Sponsor
- Fudan University
Metastatic Colorectal Cancer
Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer
The primary aim of phase II CEIL study is to evaluate the efficacy of cetuximab and envafolimab plus mFOLFOXIRI versus cetuximab plus mFOLFOX6 as first line treatment of patients with initially unresectable and previously…
- Trial name
- CEIL (NCT05959356)
- Testing
- Cetuximab + Envafolimab + mFOLFOXIRI, Cetuximab + mFOLFOX6
- Where
- 3 sites in China
- Volunteers
- 198 people
- Sponsor
- Sun Yat-sen University
Gastric / Gastroesophageal Junction Adenocarcinoma
Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Envafolimab and Lenvatinib Combined With Paclitaxel-albumin
This study is an open, exploratory clinical study. Eligible patients with advanced second-line gastric/gastroesophageal junction adenocarcinoma signed an informed consent form, were screened for enrollment, and were entered into…
- Trial name
- NCT06030934
- Testing
- envafolimab and lenvatinib combined with paclitaxel-albumin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Nasopharyngeal Carcinoma
Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma
Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma
- Trial name
- NCT06055816
- Testing
- Endostar and Envafolimab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang Cancer Hospital
Non-small Cell Lung Cancer Stage IV
Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLC
Explore the efficacy and safety of Envafolimab in first line treatment of elderly patients with locally advanced or metastatic non-small cell lung cancer with high PD-L1 expression, view to providing better treatment options for…
- Trial name
- NCT05055167
- Testing
- Envafolimab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Osteosarcoma, Neoadjuvant Therapy
Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma Patients
Given that osteosarcoma typically presents at an early age and predominantly affects pediatric and adolescent populations, early control of disease progression and the opportunity for complete tumor resection are particularly…
- Conditions
- Osteosarcoma, Neoadjuvant Therapy, Neoadjuvant Chemotherapy, PD-L1 Antibody
- Trial name
- NCT07142863
- Testing
- Envafolimab and neoadjuvant chemotherapy
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Colorectal Cancer, Mismatch Repair-deficient (dMMR)
Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer
Colorectal cancer (CRC) is one of the most common malignant tumours of human beings. Mismatch Repair-deficient (dMMR)/ Microsatellite Instability-high (MSI-H) CRC is a specific subtype of CRC, which accounts for approximately 15%…
- Conditions
- Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H), Neoadjuvant Therapy
- Trial name
- NCT05371197
- Testing
- Neoadjuvant therapy with PD-L1 inhibitor
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Metastatic Colorectal Cancer (CRC)
A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)
This is a prospective randomized controlled Phase Ⅱ/Ⅲ Clinical study to evaluate the clinical efficacy and safety of Envafolimab combining with Cetuximab -β and mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic…
- Trial name
- NCT06959693
- Testing
- Cetuxima-β, Envafolimab, mFOLFOX6
- Where
- China
- Volunteers
- 590 people
- Sponsor
- Sun Yat-sen University